Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-16
2006-05-16
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S386000, C514S408000, C514S410000, C514S416000, C514S533000, C514S642000, C514S659000
Reexamination Certificate
active
07045534
ABSTRACT:
The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a nicotinic acetyl choline receptor antagonist. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods of treating a condition associated with or resulting from angiogenesis.
REFERENCES:
patent: 4749686 (1988-06-01), Hintze
patent: 5318957 (1994-06-01), Cid et al.
patent: 6121289 (2000-09-01), Houdi
patent: 6417205 (2002-07-01), Cooke et al.
patent: 6734215 (2004-05-01), Shytle et al.
patent: 2002/0016370 (2002-02-01), Shytle et al.
patent: 2002/0016371 (2002-02-01), Shytle et al.
patent: 2004/0044083 (2004-03-01), Shytle et al.
patent: WO 00/35280 (2000-06-01), None
patent: WO 01/08684 (2001-02-01), None
Cancer, Principles & Practice of Oncology, 6th ed. Published by Lippiincott Williams & Wilkins (PA), 2001 pp 143-145,510.
Harrison's Principles of Internal Medicine, vol. 2, Isselbacher et al. eds., published 1994 by McGraw-Hill, Inc. (NY), pp1994-5.
Schuller et al. (1989)Carcinogenesis10:1753-1755.
Maneckjee et al. (1994)Cell Growth Differ. 5:1033-1040.
Hong et al. (1995)J. Pharm. Sci. 84:65-70.
Schuller et al. (1989)Biochem. Pharmacol. 38:3439-3442.
Yancopoulos et al. (1998)Cell93:661-4.
Folkman et al. (1996)Cell87;1153-5.
Hanahan et al. (1996)Cell86:353-64.
Carmeliet et al. (2000)Nature407:249-257.
Folkman (1995)Nat Med1:27-31.
Heeschen et al. (2001)Nat Med7:833-837.
Grando et al. (1995)J Invest Dermatol105:774-781.
Macklin et al. (1998)Pharmacol Exp Ther287:435-439.
Wessler et al. (1999)Clin Exp Pharmacol Physiol26:198-205.
Kawashima et al. (1989)Neurosci Lett104:336-339.
Kawashima et al. (1990)Neurosci Lett119:156-158.
Kureishi et al. (2000)Nat Med6:1004-1010.
Jang et al. (2000)Circulation102:1414-1419.
Couffinhal et al. (1998)Am J Pathol152:1667-1679.
Lagasse and Weissman (1996)J Immunol Methods197:139-150.
Villablanca (1998)J Appl Physiol84:2089-2098.
Heeschen, C. et al. “A novel anglogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors”, Journal of Clinical Investigation, New York, NY, US, vol. 110, No. 4, Aug. 2002, pp. 527-536.
B.T. Hawkins et al., “Smoking and Ischemic stroke: a role for nicotine?” Trends in Pharmacological Sciences, vol. 23, No. 2, Feb. 1, 2002, pp. 78-82.
L.E. Chavez-Noriega et al. “Characterization of the recombinant human neuronal nicotinic acetylcholine receptors alpha3beta2 and alpha4beta2 stably expressed in HEK293 cells” Neuropharmacology (2000).
Tarroni, P. et al. “Neuronal-type nicotinic receptors in human neoblastoma and small-cell lung carcinoma cell lines” FEBS Lett., 312: 66-70, 1992.
Cunningham, J.M. et al., Acetycholine receptors in small cell carcinomas, J. Neurochem., 45: 159-167, 1985.
Quik, M. et al., a-Bungaroxotin blocks the nicotinic receptor mediated increase in cell number in a neuroendocrine cell line. Brain Res., 655: 161-167, 1994.
Schuller et al. Nicotine, acetylcholine and bombesin are trophic growth factors in neuroendocrine cell line. Brain res., 655: 161-167, 1994.
Fucile et al., “Cholinergic stimulation of human micro-cytoma cell line H69” Biochem. Biophys. Res. Commun., 230: 501-504, 1997.
Novak et al., “Nicrotine effects of proliferation and the bombesin-like peptide autorcine system in hman small cell ling carcinoma SHP77 cells in culture” Lung Cancer, 29: 1-20, 2000.
Codignola, A., et al. “Serotonin release and cell proliferation are under the control of a-bungarotoxin-sensitive nicotinic receptors in small-cell lung carcinoma cell lines” FEBS Lett., 342:286-290, 1990.
Williams, C.L. and Lennon, V.A. Activation of M3 muscarinic acetylcholine receptors inhibits voltage-dependent calcium influx in small cell lung carcinoma cell. J. Biol. Chem., 265: 1443-1447, 1990.
Maneckjee, R. and Minna J.D., Opoid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc. Natl. Acad. Sci. USA, 87: 3294-3298, 1990.
Song, et al., Acetylcholine is Synthesized by and Acts as an Autocrine Growth Factor for Small Cell Lung Carcinoma, Cancer Research 63. 214-221, Jan. 1, 2003.
Cooke John
Heeschen Christopher
Weis Michael
Borden Paula A.
Bozicevic Field & Francis LLP
Francis Carol L.
Henley III Raymond J.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Methods of reducing angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of reducing angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3590528